EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MET variants with activating N‐lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation

Célia Guérin, Audrey Vinchent, Marie Fernandes, Isabelle Damour, Agathe Laratte, Rémi Tellier, Gabriella O Estevam, Jean-Pascal Meneboo, Céline Villenet, Clotilde Descarpentries, James S Fraser, Martin Figeac und 3 weitere

Molecular Oncology · 2025

DOI: 10.1002/1878-0261.13806 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Célia Guérin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to The…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-met, Carcinoma, Renal Cell, Mutation, Kidney Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancéropôle Nord-Ouest, NCI NIH HHS, Institut National du Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In hereditary papillary renal cell carcinoma (HPRCC), the hepatocyte growth factor receptor (MET) receptor tyrosine kinase (RTK) mutations recorded to date are located in the kinase domain and lead to constitutive MET activation. This contrasts with MET mutations identified in non‐small‐cell lung cancer (NSCLC), which lead to exon 14 skipping and deletion of a regulatory domain: In this latter case, the mutated receptor still requires ligand stimulation. Sequencing of MET in samples from 158 HPRCC and 2808 NSCLC patients revealed 10 uncharacterized mutations. Four of these, all found in HPRCC and leading to amino acid substitutions in the N‐lobe of the MET kinase, proved able to induce cell transformation, which was further enhanced by hepatocyte growth factor (HGF) stimulation: His1086Leu, Ile1102Thr, Leu1130Ser, and Cis1125Gly. Similar to the variant resulting in MET exon 14 skipping, the two N‐lobe MET variants His1086Leu and Ile1102Thr were found to require stimulation by HGF in order to strongly activate downstream signaling pathways and epithelial cell motility. The Ile1102Thr mutation also displayed transforming potential, promoting tumor growth in a xenograft model. In addition, the N‐lobe‐mutated MET variants were found to trigger a common HGF‐stimulation‐dependent transcriptional program, consistent with an observed increase in cell motility and invasion. Altogether, this functional characterization revealed that N‐lobe variants still require ligand stimulation, in contrast to other RTK variants. This suggests that HGF expression in the tumor microenvironment is important for tumor growth. The sensitivity of these variants to MET inhibitors opens the way for use of targeted therapies for patients harboring the corresponding mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-metCarcinoma, Renal CellMutationKidney NeoplasmsHumansAnimalsHepatocyte Growth FactorMiceLigandsCell Line, TumorFemaleSignal TransductionMale

Stichwörter der Autor:innen

METcancerhepatocyte growth factorhereditary papillary renal cancerreceptor tyrosine kinasesomatic mutations

Substanzen

Proto-Oncogene Proteins c-metHepatocyte Growth FactorMET protein, humanLigands

Autor:innen und Institutionen

  • Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.
  • Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA.
  • Univ. Lille, Plateau de génomique fonctionnelle et structurale, CHU Lille, France.
  • Department of Biochemistry and Molecular Biology, Hormonology Metabolism Nutrition Oncology, CHU Lille, France.
  • Thoracic Oncology Department, Univ. Lille, CHU Lille, France.
  • Department of Medical Biology and Pathology, Cancer Genetics Laboratory, Gustave Roussy, Villejuif, France.

ORCID-Profile: David Tulasne

Förderung

  • Cancéropôle Nord-Ouest
  • NCI NIH HHS
  • Institut National du Cancer
  • Contrat de Plan Etat Region CPER Cancer 2015-2020
  • Ligue Contre le Cancer, Comités Nord et Aisne
  • Agence Nationale de la Recherche
  • SIRIC ONCOLille
  • NIH HHS

Zitieren

APA

Guérin, C., Vinchent, A., Fernandes, M., Damour, I., Laratte, A., Tellier, R., Estevam, G. O., Meneboo, J. P., Villenet, C., Descarpentries, C., Fraser, J. S., Figeac, M., Cortot, A. B., Rouleau, E., & Tulasne, D. (2025). MET variants with activating N‐lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation. Molecular Oncology. https://doi.org/10.1002/1878-0261.13806

Vancouver

Guérin C, Vinchent A, Fernandes M, Damour I, Laratte A, Tellier R, et al. MET variants with activating N‐lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation. Molecular Oncology. 2025. doi:10.1002/1878-0261.13806

BibTeX
@article{Gurin2025,
  author = {Guérin, Célia and Vinchent, Audrey and Fernandes, Marie and Damour, Isabelle and Laratte, Agathe and Tellier, Rémi and Estevam, Gabriella O and Meneboo, Jean-Pascal and Villenet, Céline and Descarpentries, Clotilde and Fraser, James S and Figeac, Martin and Cortot, Alexis B and Rouleau, Etienne and Tulasne, David},
  title = {MET variants with activating N‐lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation},
  journal = {Molecular Oncology},
  year = {2025},
  doi = {10.1002/1878-0261.13806}
}
Kostenlos starten →